Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7086749 | 0.91 | CCR2 (0.65) | CCR2ABCB11F10GPR35 | |
| SCHEMBL5679174 | 0.86 | CCR2 (0.65) | CCR2ABCB11F10GPR35 | |
| SCHEMBL6597097 | 0.86 | CCR2 (0.80) | CCR2ABCB11F10 | |
| SCHEMBL7088120 | 0.84 | ABCB11 (0.74) | CCR2ABCB11F10GPR35 | |
| SCHEMBL2005378 | 0.84 | CCR2 (0.73) | CCR2ABCB11F10GPR35 | |
| SCHEMBL6597871 | 0.83 | CCR2 (0.80) | CCR2ABCB11F10 | |
| SCHEMBL7086878 | 0.83 | CCR2 (0.80) | CCR2ABCB11F10 | |
| SCHEMBL2003911 | 0.81 | CCR2 (0.65) | CCR2ABCB11F10GPR35 | |
| SCHEMBL2006370 | 0.81 | F10 (0.68) | CCR2ABCB11F10GPR35 | |
| SCHEMBL2006351 | 0.80 | CCR2 (0.79) | CCR2ABCB11F10GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | claimed |
| CN-1395565-A | Indole derivatives as MCP-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-02-05 | — | — | CN | claimed |
| EP-1252142-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-10-30 | — | — | EP | claimed |
| WO-2001051466-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | claimed |
| CN-1395565-A | Indole derivatives as MCP-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-02-05 | — | — | CN | disclosed |
| EP-1252142-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001051466-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | CCR2, CCR1, CCR5 | CCR2 1/4885ABCB11 391/4885F10 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.